Amid growing congressional efforts to contain drug costs, Sen. Bernie Sanders (I-Vt.) has accused Catalyst Pharmaceuticals (CPRX) of “fleecing” Americans and “immoral exploitation” by setting a “staggering” price for a recently approved drug used to treat a rare neuromuscular disorder.

In a blistering letter, Sanders accused Catalyst of “corporate greed” for charging a $375,000 list price for Firdapse, which is used to contain Lambert-Eaton myasthenic syndrome, or LEMS. Until December, patients could obtain an unapproved version for free from Jacobus Pharmaceuticals, a small, family-run company, thanks to a compassionate use program overseen by the Food and Drug Administration.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!

GET STARTED

What is it?

STAT Plus is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • Online intelligence briefings
  • Frequent opportunities to engage with veteran beat reporters and industry experts
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.

Leave a Comment

Please enter your name.
Please enter a comment.

  • Looks to me like some people at the FDA either did not do their homework on this issue or, perhaps, were influenced to not do their homework. Did they not know how cheaply is was being produced by compounding pharmacies and did they not know, from experience, that when a drug gets “orphan drug” status, its price goes through the roof?

    Perhaps, Senator Sanders should be looking at the FDA and its decision making process regarding “orphan drug” status.

  • Sanders is one of the few elected representatives telling the truth. It is time to control the price gouging and outright fraud of the pharma industry.

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy